外泌体介导的miRNA-1290抑制剂递送可增强前列腺癌中JNK依赖的组织驻留记忆T细胞免疫
核心信息
- 论文英文标题: Exosome-mediated delivery of miRNA-1290 inhibitor enhances JNK-dependent tissue-resident memory T cell immunity in prostate cancer
- 期刊: Sci Rep
- 发表年份: 2026
- DOI: 10.1038/s41598-026-43719-x
- PMID/PMCID: 41826614; PMC13111588
研究概览
This study aimed to evaluate the therapeutic efficacy and immunomodulatory mechanism of exosome-delivered miR-1290 inhibitor in a PCa mouse model. These findings support miRNA-1290 as a promising therapeutic target and highlight exosome-based RNA therapeutics as a novel strategy for prostate cancer management, warranting further translational development.
核心发现
Prostate cancer (PCa) is a leading malignancy in men, particularly challenging in its advanced stages due to treatment resistance and immune evasion.
MicroRNA-1290 (miR-1290) was identified to be implicated in tumor progression, but its role in PCa remains insufficiently characterized.
Recent advances in exosome-based delivery systems provide opportunities to target oncogenic miRNAs in vivo.
This study aimed to evaluate the therapeutic efficacy and immunomodulatory mechanism of exosome-delivered miR-1290 inhibitor in a PCa mouse model.
Echo Biotech 角色
小鼠前列腺癌细胞上清EV分离-Exosupur
关联平台: Exoomics®, Research Reagents & Tools
关联服务与能力: Cell-Culture Supernatant EV Isolation & Purification, Research Reagent / Product Supply
关联产品或试剂: Exosupur® EV Isolation/Purification Kit
参考文献
原始论文: Exosome-mediated delivery of miRNA-1290 inhibitor enhances JNK-dependent tissue-resident memory T cell immunity in prostate cancer Scientific reports. 2026. DOI: 10.1038/s41598-026-43719-x. PMID/PMCID: 41826614; PMC13111588.